 "Vivimed Labs gains on sale of certain products to Clariant Chemicals")
Vivimed Labs is trading higher by 4.4% at Rs 342 on the BSE after the company announced that it has signed a definitive agreement for the transfer and sale of certain products of its speciality chemicals divison to Clariant Chemicals.
The transaction value of identified products lines at an enterprise value of Rs 380 crore, Vivined Labs said in a release.
The part of speciality chemicals division's business, which is proposed to be divested, accounted for about 10% of the consolidation revenue from operation in FY2015. A major portion of the receipts will be used to reduce debts thereby saving substantial interest cost going forward, it added.
The stock opened at Rs 336 and touched high of Rs 348 on the BSE. A combined 454,352 shares changed hands on the counter on the BSE and NSE till 11:53 am.
The transaction value of identified products lines at an enterprise value of Rs 380 crore, Vivined Labs said in a release.
The part of speciality chemicals division's business, which is proposed to be divested, accounted for about 10% of the consolidation revenue from operation in FY2015. A major portion of the receipts will be used to reduce debts thereby saving substantial interest cost going forward, it added.
The stock opened at Rs 336 and touched high of Rs 348 on the BSE. A combined 454,352 shares changed hands on the counter on the BSE and NSE till 11:53 am.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%